Diane M. Simeone, M.D. is an Associate Professor in the Section of General Surgery,
Division of Gastrointestinal Surgery and Associate Professor of Molecular and Integrative Physiology.
Dr. Simeone received her bachelor's degree from Brown University in Providence, Rhode Island and a medical degree from Duke University Medical
School in Durham, North Carolina. She completed her General Surgery residency training in 1995 at the University of Michigan Medical Center.
She joined the faculty at the University of Michigan Medical Center in 1995. Dr. Simeone's clinical interests are in the area of gastrointestinal
oncology. She has a special interest in the surgical treatment of pancreatic adenocarcinoma, and is the Surgical Director of the Multidisciplinary
Pancreatic Cancer Clinic. Dr. Simeone is the principal director of a research laboratory that is funded by the National Institutes of Health.
Her basic science laboratory investigates mechanisms of pancreatic growth regulation and molecular events important in the development and
progression of pancreatic adenocarcinoma. She is also an associate member of the Early Detection Research Network (EDRN), an NCI-funded
initiative to identify and validate early detection biomarkers for the diagnosis of pancreatic cancer.
Director of the University of Michigan Pancreatic Cancer Center
Michelle A. Anderson, M.D., M.Sc.
Dr. Michelle A. Anderson completed her Internal Medicine residency and Gastroenterology fellowship at the University of Michigan where she trained
in advanced endoscopy including endoscopic ultrasound and ERCP. Following fellowship training, she joined the faculty at Michigan. Dr. Anderson's
clinical and research interests focus on diseases of the pancreas and biliary system with a special emphasis on chronic pancreatitis, pancreatic
cancer and therapeutic EUS and ERCP as they relate to these diseases. In 2005, she received a Masters' of Science degree in Clinical Research and
Statistical Analysis from the University of Michigan's School of Public Health. Dr. Anderson combines her clinical and research training to conduct
research to identify biomarkers to distinguish pancreatic cancer from chronic pancreatitis under funding from the NIH. She performs EUS and ERCP
in clinical practice as well as in teaching forums both nationally and internationally. She is an active member of the American Society of
Gastrointestinal Endoscopy (ASGE), the American Gastroenterological Association and the American College of Gastroenterology. Dr. Anderson is a
Fellow of the ASGE and has served on the ASGE Standards of Practice Committee and the ASGE Institute for Training and Technology for almost 10 years.
Assistant Professor, Department of Internal Medicine
Co-Director of the University of Michigan Pancreatic Cancer Center
Marina Pasca di Magliano, PhD.
Dr. Pasca di Magliano is an Assistant Professor in the Division of Surgical Oncology, Section of General Surgery. Dr. Pasca di Magliano holds a
joint appointment in Cell and Developmental Biology. Dr. Pasca di Magliano earned her B.S. in 1996 at the University of Napoli in Italy before
going on to receive her Ph.D. in 2002 at the Institute for Molecular Pathology in Vienna, Austria. Dr. Pasca di Magliano completed her postdoctoral
training at the University of California Diabetes Center in San Francisco.
Assistant Professor of Surgery
Dr. Pasca di Magliano's research concentrates on the formation and progression of pancreatic cancer, with a focus on signaling pathways, such as Hedgehog and Wnt, that are activated during carcinogenesis. In particular, how these signaling pathways mediate the interactions of tumor cells with components of the tumor stroma. Her work also explores the link between inflammation and pancreatic cancer.
Mats Ljungman, PhD.
Dr. Ljungman's lab is assisting with the examination of ATDC in DNA damage response. Over-expression of ATDC results in increased
proliferation both in vitro and in vivo and leads to increased radiation resistance. The collaboration has found that ATDC is rapidly
phosphorylated by the ATM kinase following irradiation and this leads to the re-localization of ATDC to sites of DNA damage. The lab
is currently further investigating the mechanisms by which ATDC stimulates proliferation and protects cells from ionizing radiation
and are screening for compounds that inactivates ATDC.
Professor, Radiation Oncology
Professor of Environmental Health Sciences, School of Public Health
Rajasree Menon, Ph.D.
Dr. Menon's main research is focused on studying alternative splice isoforms/variants that are involved in different types of human cancers. She has developed an
approach to integrate transcriptomic data with mass-spectrometric data for the identification of splice isoforms. The functional role of the distinct splice
variant of a gene is not well understood. She uses different computational tools to understand the potential functions and interactions of these variants. She
collaborate with other University of Michigan cancer specialists to experimentally validate our splice variant predictions in human normal and tumor tissue samples.
Computational Medicine & Bioinformatics
Sunitha Nagrath, PhD.
Dr. Nagrath's lab is developing microfluidic devices for isolating and studying cancer cells as related to metastasis.
Assistant Professor, Chemical Engineering
Metastasis occurs when cells disseminate from the primary tumor site and travel through the body's vasculature, then exit the vessels into distant tissues, adapt to the microenviroment and proliferate into new tumors.
She is using microfluidic devices to study cell migration, specifically how cancer cells enter and exit the vasculature, detecting circulating cancer cells in the blood, and studying the microenvironmental cues needed to sustain and grow tumor metastases.
Microfluidic devices allow for studying individual cell behavior, capturing rare cells, such as circulating tumor cells (CTCs), and sustaining cell cultures. Microfluidics are being created to mimic in vivo environments and will become more widely used in biology as the devices become more automated for general use.
Andrew D. Rhim, M.D.
Dr. Rhim's research program is focused on the biology of pre-cancerous lesions of epithelial organs and the molecular and cellular events that occur during their
transition to cancer. He employs unique genetically engineered mouse models of pancreatic ductal adenocarcinoma (PDAC) as a model for cancer development and progression.
The overarching goal of these studies is to learn more about how cancer evolves so that we may devise new strategies for early diagnosis and treatment for patients
with clinically occult advanced precancerous lesions and early forms of cancer.
Vaibhav Sahai MBBS
Dr. Sahai's focus lies in experimental therapeutics in pancreatic and biliary ductal carcinomas via a molecular-based approach in the laboratory with the aim to
perform translational and clinical research. In collaboration with Diane Simeone, M.D., the objective is to investigate potential compounds in collaboration with
investigators at the University of Michigan, as well as pharmaceutical companies across a platform of in-vitro and in-vivo models with the goal to take promising
compounds to phase I clinical trials.